Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020
April 27 2020 - 8:30AM
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will release financial results and business updates for the
first quarter of 2020 on Monday, May 4, 2020. The Company
will host a webcast and conference call that day at 8:30 a.m.
Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845
(domestic) or (765) 507-2618 (international) and referring to
conference ID number 3969525. A live webcast of the
conference call will be available online in the Investors and Media
section of the Company’s website at
ir.minervaneurosciences.com. The archived webcast will be
available on the Company’s website beginning approximately two
hours after the event for 30 days.
The live webcast can be accessed under “Events and
Presentations” in the Investors and Media section of Minerva’s
website at ir.minervaneurosciences.com. The archived webcast
will be available on the website beginning approximately two hours
after the event for 90 days.
About Minerva Neurosciences
Minerva’s proprietary compounds include: roluperidone (MIN-101),
in clinical development for schizophrenia; seltorexant (MIN-202 or
JNJ-42847922), in clinical development for insomnia and major
depressive disorder (MDD); and MIN-301, in pre-clinical development
for Parkinson’s disease. Minerva’s common stock is listed on
the NASDAQ Global Market under the symbol “NERV.” For more
information, please visit www.minervaneurosciences.com.
Contact:
William B. BoniVP, Investor Relations/Corp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024